Active surveillance no longer "preferred" management for low-risk prostate cancer? Really NCCN??! Jeez

This one really slipped under the radar when the National Comprehensive Cancer Centre Network (NCCN) Prostate Cancer Guideline Panel released their updated guidelines a few weeks ago. That is until Dr Dan Lin mentioned it to Dr Matt Cooperberg, who promptly flagged it to his very large Twitter following. And what a reaction! Almost universally panned by the urological community, especially advocates for active surveillance (AS), who have long despaired at the low rates of AS uptake in the US, and who worry that this change may lead to even lower rates of AS in the USA. We are joined again today by Dr Matt Cooperberg (Urologist, UCSF), and Dr Ashley Ross (Urologist, Northwestern Medical Group, Chicago), to have an in-depth discussion on this. Usual hosts Declan Murphy and Renu Eapen do their best to stay impartial! Our prediction is that NCCN will change this back at the next opportunity....Also posted on YouTube for those who like to watch facial reactions! Links:Matt Cooperberg's TweetNCCN Guideline on prostate cancer (login needed)MedPage Today report